Henlius Denosumab Biosimilar Trial Enters Phase III
As Firm’s Shanghai Plant Has Received EU GMP Equivalence
Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.
